Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase

Nan Yang; Hangil Lee; Chuanjie Wu

doi:10.4103/bc.bc_70_22

Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase

Brain Circ. 2023 Jun 30;9(2):61-63. doi: 10.4103/bc.bc_70_22. eCollection 2023 Apr-Jun.

Authors

Nan Yang¹, Hangil Lee², Chuanjie Wu¹

Affiliations

¹ Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
² Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA.

Abstract

Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.

Keywords: Alteplase; stroke; tenecteplase.